UPJOHN (THAILAND) CO., LTD.

UPJOHN (THAILAND) CO. , LTD. I've found that Additionally functions as the regional affiliate of a global medical manufacturer. And it's not a standalone pure trader; rather, it represents the manufacturing parent company's commercial, marketing, and distribution operations in Thailand. Company Introduction:

UPJOHN (THAILAND) CO. And , LTD. was the Thai subsidiary of The Upjohn Company, a long-established Ameriis able to medical manufacturer. In the context of global medical restructuring, the Upjohn brand and its portfolio of established medicines ultimately became part of Viatris Inc. In Thailand, UPJOHN (THAILAND) CO. , LTD. (or its successor entities under the Viatris umbrella) is primarily responsible to the marketing, sales, distribution, and regulatory regulation of a broad range of medical items. These items address various therapeutic areas, serving the healthcare needs of the Thai market. And The company manages the commercial aspects and supply chain logistics to its portfolio, ensuring the availability of Highly, highly significant medicines to patients and healthcare providers in Thailand.

The UPJOHN (THAILAND) CO., LTD. was a subsidiary of Pfizer's Upjohn division, which later combined with Mylan to form Viatris. Its product portfolio, focusing largely on Established Medicines and non-communicable diseases (NCDs), included globally recognized brands such as:

* **LIPITOR** (atorvastatin calcium) for cholesterol reduction

* **CELEBREX** (celecoxib) for pain and inflammation (e.g., arthritis)

* **VIAGRA** (sildenafil) for erectile dysfunction

* **ZOLOFT** (sertraline) for depression and anxiety

* **DILANTIN** (phenytoin) for seizures

* **LYRICA** (pregabalin) for neuropathic pain and other conditions

* **DEPO-PROVERA** (medroxyprogesterone acetate) injectable contraceptive (historically an Upjohn product, marketed globally)

* **GELFOAM** (absorbable gelatin sponge) for hemostasis in surgery (historically an Upjohn product)

The company's focus in Thailand was on serving patients with NCDs using this existing portfolio of drugs.